Condition (MeSH)
Castleman Disease
ClinicalTrials.gov lists 22 trials for Castleman Disease or a narrower condition beneath it. National Cancer Institute (NCI) has the most among industry and government lead sponsors, with 2.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
22 of the 22 trials are tagged with Castleman Disease itself; the rest are tagged with a narrower condition beneath it.
When did Castleman Disease trials start? (17)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 2
- Phase 4
- Not applicable
- Observational
Top of scale: 3
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2025 | 1 |
| 2024 | 1 |
| 2023 | 1 |
| 2021 | 3 |
| 2020 | 1 |
| 2019 | 1 |
| 2018 | 1 |
| 2017 | 1 |
| 2016 | 3 |
| 2014 | 1 |
Showing 10 of 17 earlier years.
No forecast is made for this condition: it averages 0.6 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Castleman Disease trials in? (5)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 5 |
| Phase 2 | 5 |
| Phase 4 | 1 |
| Not applicable | 1 |
| Observational | 10 |
How many Castleman Disease trials are recruiting? (8)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 1 |
| Recruiting | 7 |
| Active, not recruiting | 1 |
| Completed | 5 |
| Suspended | 1 |
Showing 5 of 8 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Castleman Disease trials? (5)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Cancer Institute (NCI) | 2 |
| Centocor, Inc. | 1 |
| Cylene Pharmaceuticals | 1 |
| French National Agency for Research on AIDS and Viral Hepatitis | 1 |
| Hoffmann-La Roche | 1 |
Which drugs are being tested for Castleman Disease? (5)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Zidovudine | 1 |
| RITUXIMAB | 1 |
| Temsirolimus | 1 |
| Nelfinavir | 1 |
| CETUXIMAB | 1 |
Interventions as named in the registry (10)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Valganciclovir | 2 |
| L01XE31 - Nintedanib | 1 |
| tocilizumab [RoActemra] | 1 |
| Ruxolitinib IR | 1 |
| Siltuximab11 mg/kg | 1 |
Showing 5 of 10 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Castleman Disease trials report? (3)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Fever | 1 | 1 |
| Pneumonia | 1 | 1 |
| Sepsis | 1 | 1 |
Which publications cover Castleman Disease? (46)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Inflammasome activation in patients with Kaposi sarcoma herpesvirus-associated diseases. | Blood | 2024 | Yes |
| Siltuximab administration results in spurious IL-6 elevation in peripheral blood. | American journal of hematology | 2024 | Yes |
| Immune-mediated thrombocytopenia and IL-6-mediated thrombocytosis observed in idiopathic multicentric Castleman disease. | British journal of haematology | 2024 | Yes |
| A prospective study of zanubrutinib, a Bruton tyrosine kinase inhibitor, in relapsed/refractory idiopathic multicentric Castleman disease. | International journal of hematology | 2024 | Yes |
| Ongoing symptoms following complete surgical excision in unicentric Castleman disease. | American journal of hematology | 2023 | Yes |
Showing 5 of 46 publications.
Prevalence (6)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Castleman disease | Annual incidence | 1-9 / 100 000 | United States | US | Exact |
| Castleman disease | Annual incidence | 1-9 / 100 000 | United States | US | Exact |
| Castleman disease | Annual incidence | 1-9 / 100 000 | United States | US | Unspecified |
| Castleman disease | Point prevalence | Unknown | Worldwide | Not stated | Exact |
| Castleman disease | Point prevalence | Unknown | Worldwide | Not stated | Exact |
Showing 5 of 6 prevalence observations.
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Castleman disease | 160 | Exact | Orphadata Science knowledge files, Product 1 |
| Castleman disease | 160 | Exact | Orphanet Rare Disease Ontology (ORDO) |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: sub-conditions in mesh.